Metyrapone: a management option for ectopic ACTH syndrome in small cell lung cancer treated with intravenous etoposide. - Suppr | 超能文献

Metyrapone: a management option for ectopic ACTH syndrome in small cell lung cancer treated with intravenous etoposide.

作者信息

Aziz Shaikh Irfan, Khattak Muhammad Adnan, Usmani Zafar, Ladipeerla Narsing, Pittman Ken

机构信息

Department of Endocrinology, The Queen Elizabeth Hospital, Adelaide, Australia.

出版信息

BMJ Case Rep. 2011 Aug 4;2011:bcr0420102917. doi: 10.1136/bcr.04.2010.2917.

DOI:10.1136/bcr.04.2010.2917

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4545102/

Abstract

Small cell lung cancer (SCLC) with ectopic adrenocorticotropic hormone (ACTH) syndrome and resultant hypercortisolism carries a poor prognosis with a short median survival and high incidence of infective complications. The combination of etoposide with either carboplatin or cisplatin is the current standard chemotherapy used for the management of SCLC. Etoposide is metabolised by cytochrome P450 3A4. Ketoconazole is an imidazole derivative possessing antifungal properties and also causes inhibition of adrenal corticosteroid and androgen production. There is an additional increased risk of toxicity due to a potential interaction between etoposide and ketoconazole, which is a strong inhibitor of cytochrome P450 3A4, and theoretically can lead to greater myelosuppression. Metyrapone can be a safe alternative in such settings.

摘要

相似文献

1

Metyrapone: a management option for ectopic ACTH syndrome in small cell lung cancer treated with intravenous etoposide.

BMJ Case Rep. 2011 Aug 4;2011:bcr0420102917. doi: 10.1136/bcr.04.2010.2917.

2

Syndrome of inappropriate antidiuretic hormone secretion and ectopic ACTH production in small cell lung carcinoma.

Lung Cancer. 2007 Jul;57(1):120-2. doi: 10.1016/j.lungcan.2007.03.003. Epub 2007 Apr 5.

3

Spontaneous adrenocorticotropic hormone (ACTH) normalisation due to tumour regression induced by metyrapone in a patient with ectopic ACTH syndrome: case report and literature review.

BMC Endocr Disord. 2018 Mar 27;18(1):19. doi: 10.1186/s12902-018-0246-2.

4

Marked increase in plasma ACTH with tumor reduction after chemotherapy in ectopic ACTH syndrome.

Endocr J. 1999 Apr;46(2):331-5. doi: 10.1507/endocrj.46.331.

5

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.

6

[Small cell lung cancer with Sézary syndrome].

Nihon Kokyuki Gakkai Zasshi. 2009 Dec;47(12):1135-40.

7

The feasibility study of Carboplatin plus Etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias.

J Thorac Oncol. 2011 Apr;6(4):801-7. doi: 10.1097/JTO.0b013e3182103d3c.

8

Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer.

J Clin Oncol. 1992 Jan;10(1):21-7. doi: 10.1200/JCO.1992.10.1.21.

9

Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

J Natl Cancer Inst. 1997 Apr 16;89(8):577-80. doi: 10.1093/jnci/89.8.577.

10

Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.

Medicine (Baltimore). 2017 Oct;96(42):e8176. doi: 10.1097/MD.0000000000008176.

引用本文的文献

1

Refractory postoperative Staphylococcus hominis bacteremia in a patient with an ACTH-producing pancreatic neuroendocrine neoplasm: a case report.

Surg Case Rep. 2022 Jun 29;8(1):126. doi: 10.1186/s40792-022-01485-8.

2

Beyond the Dual Paraneoplastic Syndromes of Small-Cell Lung Cancer with ADH and ACTH Secretion: A Case Report with Literature Review and Future Implications.

Case Rep Oncol Med. 2018 Oct 18;2018:4038397. doi: 10.1155/2018/4038397. eCollection 2018.

3

Comparison of tumor related signaling pathways with known compounds to determine potential agents for lung adenocarcinoma.

Thorac Cancer. 2018 Aug;9(8):974-988. doi: 10.1111/1759-7714.12773. Epub 2018 Jun 5.

本文引用的文献

1

Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.

Cancer Chemother Pharmacol. 2007 Nov;60(6):811-9. doi: 10.1007/s00280-007-0428-5. Epub 2007 Feb 17.

2

A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes.

J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.

3

Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications.

Arch Intern Med. 1993 Mar 22;153(6):746-52.

4

Endocrine function in small cell undifferentiated carcinoma of the lung.

Cancer. 1982 Nov 15;50(10):2147-53. doi: 10.1002/1097-0142(19821115)50:10<2147::aid-cncr2820501029>3.0.co;2-m.

5

Hormonal polypeptides and amine metabolites in small cell carcinoma of the lung, with special reference to stage and subtypes.

Cancer. 1980 Mar 15;45(6):1432-7. doi: 10.1002/1097-0142(19800315)45:6<1432::aid-cncr2820450622>3.0.co;2-z.

6

Ketoconazole. Use in the treatment of ectopic adrenocorticotropic hormone production and Cushing's syndrome in small-cell lung cancer.

Arch Intern Med. 1985 May;145(5):863-4. doi: 10.1001/archinte.145.5.863.

7

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

J Clin Oncol. 1992 Oct;10(10):1635-42. doi: 10.1200/JCO.1992.10.10.1635.

8

Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer.

J Clin Oncol. 1992 Jan;10(1):21-7. doi: 10.1200/JCO.1992.10.1.21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。